Ask about this productRelated genes to: HOXA11 Blocking Peptide
- Gene:
- HOXA11 NIH gene
- Name:
- homeobox A11
- Previous symbol:
- HOX1I, HOX1
- Synonyms:
- -
- Chromosome:
- 7p15.2
- Locus Type:
- gene with protein product
- Date approved:
- 1990-07-05
- Date modifiied:
- 2019-04-23
- Gene:
- HOXA11-AS NIH gene
- Name:
- HOXA11 antisense RNA
- Previous symbol:
- HOXA11AS
- Synonyms:
- HOXA11-AS1, HOXA11S, HOXA-AS5, NCRNA00076
- Chromosome:
- 7p15.2
- Locus Type:
- RNA, long non-coding
- Date approved:
- 2008-06-20
- Date modifiied:
- 2018-07-26
Related products to: HOXA11 Blocking Peptide
Related articles to: HOXA11 Blocking Peptide
- Idiopathic Pulmonary Fibrosis (IPF) is characterized primarily by progressive lung tissue scarring. This study aimed to explore the molecular mechanism of the HOXA11-AS/miR-148a-3p/SMAD2 axis in IPF. - Source: PubMed
Publication date: 2026/05/14
Wang LidongDing XingTang RanJiang Heping - This study aimed to investigate the expression and evaluate the function of long non-coding RNA (LncRNA) HOXA11-AS in Esophageal Squamous Cell Carcinoma (ESCC). HOXA11-AS expression was quantified in paired ESCC tumor tissues (n = 50) and adjacent histologically normal tissues (> 5 cm from tumor margin) (n=50) from surgical patients. The relationship between HOXA11-AS expression levels, clinical staging and patient survival was analyzed. Lentiviral transduction was employed to generate stable ESCC cell lines with HOXA11-AS overexpression (lv-HOXA11-AS) or knockdown (sh-HOXA11-AS), accompanied by negative control groups (lv-NC/sh-NC). The impact on malignant phenotype was assessed via CCK-8 proliferation assays, Transwell migration/invasion assays, wound healing assays, and flow cytometry for apoptosis. In vivo tumor growth was evaluated by subcutaneously injecting fluorescently labeled lv-HOXA11-AS or lv-NC cells into BALB/c-nu mice. RNA-sequencing and tissue qRT-PCR confirmed significantly higher HOXA11-AS expression in ESCC versus normal epithelium, and high HOXA11-AS expression was associated with advanced tumor stage and was identified as an independent predictor of poor prognosis. qRT-PCR validated the elevated expression of HOXA11-AS in ESCC cell lines too. HOXA11-AS overexpression promoted proliferation, migration, invasion, and suppressed early apoptosis in ESCC cells, HOXA11-AS knockdown exerted opposing effects. HOXA11-AS overexpression significantly enhanced tumor growth in mouse xenograft models. LncRNA HOXA11-AS is aberrantly overexpressed in ESCC and functions as an oncogene, driving tumor progression by enhancing proliferation, migration, invasion and suppressing apoptosis. Its association with poor prognosis identifies HOXA11-AS as a promising prognostic biomarker and potential therapeutic target for ESCC. - Source: PubMed
Publication date: 2025/09/26
Li WanwenXie ShenglongLiu HaiqiLi WeiHe Bin - Long non-coding RNAs (lncRNAs) are increasingly recognized in keloid pathogenesis. This study investigates the role and mechanisms of HOXA11-AS in keloid formation. - Source: PubMed
Publication date: 2025/08/12
Jin JunWang KaiLu ChenxiYao ChenghaoXie Feng - - Source: PubMed
Publication date: 2025/08/05
Zhang YuChen Wen-JieGan Ting-QingZhang Xiu-LingXie Zu-ChengYe Zhi-HuaDeng YunWang Ze-FengCai Kai-TengLi Shi-KangLuo Dian-ZhongChen Gang - Recently, research on the competing endogenous RNAs (ceRNAs) in cancer has been in full swing, emphasizing their importance as critical RNAs in cancer progression. Enhancer of zeste 2 polycomb repressive complex 2 subunit () is a ceRNA that has been introduced as a potential therapeutic target in many cancers. Due to EZH2's dual role as an oncogene and tumor suppressor in cancer, a more thorough exploration of its ceRNA functions may enhance clinical cancer treatment approaches. In the current scoping review, we searched several online databases to identify experimentally validated ceRNA axes, including in human cancers. We identified 66 unique axes consisting of 30 microRNAs (miRNAs), 32 long non-coding RNAs (lncRNAs), 9 messenger RNAs (mRNAs), and 14 circular RNAs (circRNAs). Notably, miR-101-3p - and miR-101-3p - were recurrent axes observed in multiple cancer types. Among the most frequent miRNAs were miR-101-3p, miR-144-3p and miR-124-3p, and ceRNAs including , , , , , and emerged as frequent competitors of for miRNA binding. This scoping review highlights the diversity of -containing ceRNA axes in cancer, suggesting their potential as therapeutic targets. Further studies are needed to clarify their roles and clinical utility. - Source: PubMed
Publication date: 2025/05/31
Salehi-Mazandarani SadraMahmoudian-Hamedani ShararehFarajzadegan ZibaNikpour Parvaneh